Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Boost Measures to Ensure COVID Drug Access, Govt Says after Shionogi Antiviral Delay
July 22, 2022
- Label Expansions for Onoact, Ultomiris Up for MHLW Panel Review on Aug. 4
July 22, 2022
- Komeito Lawmakers Call for Assessing Shionogi’s Pill for Circulating Strains
July 22, 2022
- Japan Plans Smaller Drug Price Survey for 2023 Revision, Just Like 2 Years Ago
July 21, 2022
- Imfinzi, Bavencio to Add Encephalitis Risks in Label Revision
July 21, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Up for Review on Aug. 3
July 21, 2022
- Novo’s Rybelsus in for Price Cuts as Chuikyo OKs CEA Results
July 21, 2022
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
- PMDA Head Fujiwara Re-Elected as ICMRA Vice Chair
July 20, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Up for MHLW Panel Review on July 29
July 19, 2022
- Japan Panel to Discuss 4th COVID Shot to Healthcare Providers: Health Minister
July 19, 2022
- MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- MHLW Mulls Data Collection Policy for Conditionally Approved MSC Therapies
July 14, 2022
- Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
- Govt Council Calls for Steps to Beef Up Japan’s Clinical Trial System for Vaccines
July 13, 2022
- Accelerate Social Implementation of Genomic Medicine: Study Group
July 13, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…